At Bristol Myers Squibb, we are pursuing bold science in Immunology to deliver transformational solutions that address unmet needs for patients. Fueled by our deep understanding of the immune system that spans more than 20 years of experience, we are driven to deliver life-changing medicines that elevate new standards of care — helping to relieve the burdens of conditions like pulmonary fibrosis.
Pulmonary fibrosis is a chronic, life-threatening interstitial lung disease (ILD) that occurs when lung tissue becomes damaged and scarred, impairing lung function and resulting in daily symptoms such as chronic cough, extreme breathlessness and severe fatigue often experienced after exercise, household activities or social activities. Currently approved therapies can slow the decline in lung function, but unmet needs remain. Hear Bruce Ellsworth, PhD, scientific executive director, Medicinal Chemistry, and Aditya Patel, MD, clinical program lead for pulmonology, discuss how Bristol Myers Squibb is leveraging its deep expertise in drug discovery and disease biology to investigate potential treatments for pulmonary fibrosis.
Aditya: Pulmonary fibrosis is often a devastating illness. Living with the disease may include daily symptoms such as coughing, labored breathing and fatigue. Many people are physically impaired and have difficulty performing simple activities due to breathlessness.
Many patients or their loved ones have never heard of the disease. As they learn more about the condition, the shock and weight of the diagnosis can be life-altering, not unlike that seen in patients diagnosed with cancer. The realization that their lives will be forever changed as they care for their health, with potentially only a few years left to live, often leads to fear, depression, isolation and hopelessness.
Aditya: While the introduction of approved therapies for idiopathic pulmonary fibrosis (IPF) in 2014 was a breakthrough, unmet needs still remain. Patients often are forced to make tradeoffs between managing their symptoms and living their lives all while their condition worsens. There remains an unmet need for more tolerable medicines that can stop the progression of pulmonary fibrosis.
Bruce: Large cross-functional groups of our scientists work in lockstep to solve complex biological problems. The discovery process starts when our team identifies a pressing unmet medical need. My team of chemists build hypotheses for the most promising compounds and they synthesize these molecules. Then, together with biologists, drug metabolism and pharmacokinetics (DMPK) scientists and other researchers, we pinpoint the most promising molecules that may change and improve how the disease in question is treated. Our colleagues in development and commercialization then carry forward our findings to evaluate the most promising molecule in clinical trials, with the ultimate goal of gaining approval for medicines that address unmet patient needs.
In the case of pulmonary fibrosis, previous research told us that blocking lysophosphatidic acid receptor 1 (LPA1) receptors may have the potential to benefit patients with lung injury and fibrosis.
Learn more about Bristol Myers Squibb's commitment to developing new treatments for immune-mediated diseases with our research on the LPA1 receptor and its role in idiopathic pulmonary fibrosis and progressive pulmonary fibrosis.
Aditya: We have a great appreciation for the heterogeneity in pulmonary fibrosis. We are currently investigating potential therapies in not only IPF, but also progressive pulmonary fibrosis (PPF), which is the clinical designation to describe patients who have ILD with a progressive fibrotic phenotype. This includes connective tissue disease-related lung disease, such as rheumatoid-related lung fibrosis and scleroderma-related lung fibrosis, and other types, such as environmental lung fibrosis.
The study of these diseases is critical because it addresses the broader spectrum of lung fibrosis and patients with these autoimmune and environmental types of lung fibrosis are often considerably younger and from a more diverse population than IPF patients.
Bruce: Fibrosis is a part of the natural wound-healing process gone awry. Our goal is to reset that balance. Lung injury stimulates LPA production and causes scarring (fibrosis), so we're trying to stop LPA over-activation.
Aditya: There may be the potential to use LPA1 antagonists in combination with established pulmonary fibrosis therapies, and it is also possible they could be taken alongside immunosuppressive medications for other conditions. This is what we’re investigating: a therapy with the potential to meet the diverse unmet needs of pulmonary fibrosis patients. That’s our ultimate goal, and that’s what drives us.
Beyond just relevant information about Bristol Myers Squibb's therapeutic areas and innovation, Our stories offer a window into the work our employees do every day for patients.
Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. As global citizens, we work sustainably and responsibly to create a positive impact in the communities where we live and work.